Company Registration No. 14465493 (England and Wales)
Endocrine Global Limited
Unaudited accounts
for the period from 7 November 2022 to 30 November 2023
Endocrine Global Limited
Unaudited accounts
Contents
Endocrine Global Limited
Company Information
for the period from 7 November 2022 to 30 November 2023
Directors
Vanitha Karunakaran
Sakthi Anand Velusamy
Company Number
14465493 (England and Wales)
Registered Office
24 Imber Close
Esher
Surrey
KT10 8EB
England
Endocrine Global Limited
Statement of financial position
as at 30 November 2023
Cash at bank and in hand
37,260
Creditors: amounts falling due within one year
(27,579)
Called up share capital
100
Profit and loss account
26,759
Shareholders' funds
26,859
For the period ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 28 January 2022 and were signed on its behalf by
Sakthi Anand Velusamy
Director
Company Registration No. 14465493
Endocrine Global Limited
Notes to the Accounts
for the period from 7 November 2022 to 30 November 2023
Endocrine Global Limited is a private company, limited by shares, registered in England and Wales, registration number 14465493. The registered office is 24 Imber Close, Esher, Surrey, KT10 8EB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
25% SLM
4
Tangible fixed assets
Motor vehicles
Computer equipment
Total
Cost or valuation
At cost
At cost
Additions
20,105
2,800
22,905
At 30 November 2023
20,105
2,800
22,905
Charge for the period
5,026
701
5,727
At 30 November 2023
5,026
701
5,727
At 30 November 2023
15,079
2,099
17,178
5
Creditors: amounts falling due within one year
2023
Taxes and social security
2,214
Loans from directors
23,865
Endocrine Global Limited
Notes to the Accounts
for the period from 7 November 2022 to 30 November 2023
6
Average number of employees
During the period the average number of employees was 1.